Effect of GSTP1 and ABCC4 gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-5-fluorouracil-based chemotherapy in Bangladeshi breast cancer patients

• Published in: Tumor biology Vol. 36; no. 7; pp. 5451 - 5457
• Main Authors: Islam, Md. Siddiqul, Islam, Mohammad Safiqul, Parvin, Salma, Ahmed, Maizbah Uddin, Sayeed, Muhammad Shahdaat Bin, Uddin, Mir Muhammad Nasir, Hussain, Syed Md Akram, Hasnat, Abul
• Format: Journal Article
• Language: English
• Published: Dordrecht Springer Netherlands 01-07-2015; Springer Nature B.V
• Subjects: Adult; Aged; Bangladesh; Biomarkers, Pharmacological; Biomedical and Life Sciences; Biomedicine; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Breast Neoplasms - pathology; Cancer Research; Chemotherapy; Cyclophosphamide - administration & dosage; Epirubicin - administration & dosage; Female; Fluorouracil - administration & dosage; Genetic Association Studies; Genetic Predisposition to Disease; Genotype; Glutathione S-Transferase pi - genetics; Humans; Middle Aged; Multidrug Resistance-Associated Proteins - genetics; Polymorphism; Polymorphism, Single Nucleotide; Research Article; Toxicity; Bangladesh; 5-fluorouracil; Cyclophosphamide; Chemotherapy; Breast cancer; Epirubicin; Polymorphisms
• ISSN: 1010-4283; 1423-0380
• DOI: 10.1007/s13277-015-3211-y

The most important cytotoxic drug namely, cyclophosphamide used in breast cancer along with epirubicin and 5-fluorouracil, is transported by ABCC transporters and detoxified by glutathione S-transferases (GSTs). The activities of these enzymes and transporters may vary in different population due to the presence of genetic polymorphisms. This study was aimed to evaluate the effects of GSTP1rs1695 and ABCC4rs9561778 polymorphisms on the response and toxicities produced by chemotherapy used in the treatment of Bangladeshi breast cancer patients. A total of 200 and 56 patients with invasive breast cancers were recruited from different public and private hospitals of Bangladesh of which 117 patients received neoadjuvant chemotherapy to examine the response as well as the toxicity, and another 139 patients received adjuvant chemotherapy to evaluate only the toxicity. Genetic polymorphisms of the mentioned genes were detected by using Polymerase Chain Reaction Restriction Fragment Length Polymorphism (PCR RFLP). Patients carrying AG and AG plus GG genotype of GSTP1rs1695 were more likely to have a good response, whereas no association of ABCC4rs9561778 was found with the chemotherapy response. Patients carrying GT and GT plus TT genotypes of ABCC4rs9561778 were found to be associated with anemia, neutropenia, leukopenia, and gastrointestinal toxicities when compared with GG genotype whereas no association was found with thrombocytopenia. GSTP1rs1695 was not associated with any type of toxicities investigated. Our result indicates that GSTP1rs1695 polymorphism was strongly associated with the response of chemotherapy, whereas ABCC4rs9561778 polymorphism was significantly related with chemotherapy-induced toxicities.